U.S. markets close in 16 minutes
  • S&P 500

    4,188.68
    +21.09 (+0.51%)
     
  • Dow 30

    34,469.64
    +239.30 (+0.70%)
     
  • Nasdaq

    13,574.30
    -8.12 (-0.06%)
     
  • Russell 2000

    2,223.01
    -18.35 (-0.82%)
     
  • Crude Oil

    64.80
    -0.83 (-1.26%)
     
  • Gold

    1,814.40
    +30.10 (+1.69%)
     
  • Silver

    27.47
    +0.97 (+3.65%)
     
  • EUR/USD

    1.2066
    +0.0057 (+0.47%)
     
  • 10-Yr Bond

    1.5610
    -0.0230 (-1.45%)
     
  • GBP/USD

    1.3895
    -0.0013 (-0.09%)
     
  • USD/JPY

    109.0520
    -0.1370 (-0.13%)
     
  • BTC-USD

    55,921.61
    -1,275.60 (-2.23%)
     
  • CMC Crypto 200

    1,449.48
    -21.93 (-1.49%)
     
  • FTSE 100

    7,076.17
    +36.87 (+0.52%)
     
  • Nikkei 225

    29,331.37
    +518.77 (+1.80%)
     

AbbVie says not seeking accelerated approval for lung cancer drug

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

March 22 (Reuters) - Drugmaker AbbVie Inc said on Thursday it will not seek accelerated approval for its experimental lung cancer treatment based on results from a mid-stage study.

The study was testing the company's Rova-T as a treatment for patients with small cell lung cancer who did not respond to at least two prior regimens.

Late-stage trials testing the drug as a treatment for patients in the earlier stages of the disease will continue, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva)